FIELD: medicine, pharmaceutics.
SUBSTANCE: present group of inventions refers to medicine, namely to endocrinology, and concerns diabetes treatment. That is ensured by administering a combination of exenatide and dalargin in effective amount, or a based drug.
EFFECT: effective diabetes treatment ensured by potentiated hypoglycemic and hypocholesteremic action of exenatide.
13 cl, 6 ex, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING DIABETES MELLITUS IN COMPLEX WITH DALARGIN | 2023 |
|
RU2816021C1 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING VASCULAR DISORDERS AND NEUROPATHIES | 2013 |
|
RU2521199C1 |
| EXENATID ANALOGUES | 2010 |
|
RU2422461C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY-RELATED DISEASES CONTAINING INSULINOTROPIC PEPTIDE CONJUGATE | 2008 |
|
RU2446816C2 |
| METHOD OF IMPROVEMENT OF LIVER FUNCTION | 2013 |
|
RU2653478C2 |
| MEANS FOR TREATING DIABETES | 2000 |
|
RU2165767C1 |
| COMPOSITIONS FOR DRUG INTRODUCTION | 2009 |
|
RU2554814C2 |
| D-TAGATOSE COMPOSITIONS AND METHODS OF PREVENTING AND TREATING ATHEROSCLEROSIS, METABOLIC SYNDROME AND SYMPTOMS THEREOF | 2009 |
|
RU2484827C2 |
| METHOD OF TREATING IL-1BETA-DEPENDENT DISEASES | 2007 |
|
RU2554747C9 |
| AGENT FOR TREATING DIABETES, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DISEASES | 2011 |
|
RU2482868C1 |
